Moreover, they established that the phosphorylated insulin-like growth factor-1 receptor (p-IGF-1R)/PI3K/AKT/mTOR signaling pathway was the target of Luteolin for reducing the migration of glioblastoma cells [102]. Here, MTOR is linked to glioblastoma.